Fig. 6.

A proresolving peptide nanotherapy for site-specific treatment of inflammatory bowel disease. (A-B) Schematic illustration of engineering of a ROS-responsive peptide nanotherapy (AON) (A) and targeted treatment of colitis (B). (C-E) TEM (C) and SEM (D) images as well as size distribution (E) of AON. Scale bars, 200 nm. (F) In vitro release profiles of Ac2-26 nanotherapies AON and APN in 0.01 M PBS at pH 7.4 with or without 1.0 mM H₂O₂. (G) Ac2-26 release in buffers simulating the gastrointestinal pH conditions. (H) Selective accumulation of AON in the inflamed colons of mice with acute colitis. (I-J) Representative digital photos (I) and quantified lengths (J) of colonic tissues isolated from mice after 7 days of treatment. Scale bars, 5 mm. (K) H&E-stained histological sections of colonic tissues. AON, Ac2-26-loaded OxbCD nanoparticles; APN, Ac2-26-loaded PLGA nanoparticles; ON, the blank OxbCD nanoparticles. *p < 0.05, **p < 0.01, ***p < 0.001. Reproduced with permission [321]. Copyright 2019, Wiley-VCH.